Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dual-target antiviral intervention in high-risk HBV-related liver cancer population
ChiCTR2600133999Phase 4Not yet recruiting
- Sponsor
- Second Affiliated Hospital of Xi'an Jiaotong University
- Start
- Aug 2026
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label trial of peginterferon alfa-2b in Chronic Hepatitis B (CHB) and hepatocellular carcinoma (HCC) (2 arms), sponsored by Second Affiliated Hospital of Xi'an Jiaotong University. Primary endpoints: Incidence of hepatocellular carcinoma, Predictive efficacy of serum markers and 1 more. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
peginterferon alfa-2b
03
Conditions
Chronic Hepatitis B (CHB)hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2600133999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600133999.